Pharma stocks showed resilience on July 9, with several companies like Laurus Labs and Lupin rising up to 3%. US President Donald Trump has reiterated that he would impose very high tariffs on ...

Stock analysts noted that Indian companies like Zydus, Dr Reddy’s Labs, Lupin, Aurobindo, and Sun Pharma are heavily reliant on the US market – with US sales contributing 30-50 per cent of ...

Aurobindo Pharma shares tumbled over 3 percent to trade at Rs 1,147 apiece in the morning, while Lupin shares dropped nearly 3 percent to trade at Rs 1,925 apiece.

The move is part of Lupin's broader strategy to create a specialised consumer healthcare entity, particularly aimed at capitalising on India's burgeoning self-care market.

Global pharma major Lupin Limited (Lupin) announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for ...

Stocks to buy: Axis Securities maintains a 'buy' on Aurobindo Pharma and Lupin, expecting strong performance in the pharmaceutical sector, driven by complex generics. The hospital sector also ...

FDA gives Lupin OK for generic Xarelto Rivaroxaban tablets have several indications, including reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.

Drugmaker Lupin has received U.S. Food and Drug Administration (U.S. FDA) approval for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg, its generic version of Janssen Pharmaceuticals’ blood ...

'Lupin' season 4 Carrousel Netflix has confirmed the fourth season of hit French series Lupin with Omar Sy in the lead role as production begin in Paris.

Lupin the IIIrd: The Movie is kicking it oldschool with a welcome return to form for its classic animated action-comedy mystery franchise..

Pharma stocks plummet as Trump threatens tariffs, impacting US-dependent companies and leading to market volatility.

Lupin Healthcare, a wholly owned subsidiary of Slough-based Lupin, has acquired a pharmaceutical company which is the sole supplier of four specialty products addressing unmet medical needs in the UK.